<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">SS</journal-id><journal-title-group><journal-title>Surgical Science</journal-title></journal-title-group><issn pub-type="epub">2157-9407</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ss.2022.1311059</article-id><article-id pub-id-type="publisher-id">SS-121396</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Breast Cancer in Young Women about 87 Cases in the General Surgery Department CHU Gabriel Tour&#233;
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Maïga</surname><given-names>Amadou</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Saye</surname><given-names>Zakari</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sidibé</surname><given-names>Boubacar Yoro</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Diakité</surname><given-names>Ibrahima</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Bah</surname><given-names>Amadou</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Diallo</surname><given-names>Mahamadou</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Diallo</surname><given-names>Aly Boubacar</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Traoré</surname><given-names>Bathio</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Moussa</surname><given-names>Diassana</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Koné</surname><given-names>Tani</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Doumbia</surname><given-names>Arouna Adama</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Traoré</surname><given-names>Amadou</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Diallo</surname><given-names>Mamadou</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Traoré</surname><given-names>Djibril</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Konaté</surname><given-names>Moussa</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Saadé</surname><given-names>Oumou Hélène</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kanté</surname><given-names>Lassana</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Konaté</surname><given-names>Madiassa</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Dembélé</surname><given-names>Souleymane</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Samaké</surname><given-names>Moussa</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Keita</surname><given-names>Mory</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Dembélé</surname><given-names>Bakary Tientigui</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Traoré</surname><given-names>Alhassane</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Togo</surname><given-names>Adégné</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>Department of Orthopedic Traumatology, University Hospital, Bamako, Mali</addr-line></aff><aff id="aff5"><addr-line>Reference Center of Commune VI, Bamako, Mali</addr-line></aff><aff id="aff4"><addr-line>General Surgery Department, Mopti Hospital, Mopti, Mali</addr-line></aff><aff id="aff1"><addr-line>Department of General Surgery, University Hospital, Bamako, Mali</addr-line></aff><aff id="aff2"><addr-line>Department of General Surgery, Sikasso Hospital, Sikasso, Mali</addr-line></aff><pub-date pub-type="epub"><day>21</day><month>11</month><year>2022</year></pub-date><volume>13</volume><issue>11</issue><fpage>506</fpage><lpage>517</lpage><history><date date-type="received"><day>17,</day>	<month>August</month>	<year>2022</year></date><date date-type="rev-recd"><day>20,</day>	<month>November</month>	<year>2022</year>	</date><date date-type="accepted"><day>23,</day>	<month>November</month>	<year>2022</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Our objectives were to determine the frequency of breast cancer in young women, to determine the risk factors for breast cancer in young women, to detail the diagnostic process of the disease, to determine the different therapeutic strategies.
   
  This was a retrospective and descriptive study going from January 2005 to December 2021, a period of 17 years. The study involved 87 women with an average age of 33.2 years. Patients consulted 66 times or 75.9% for breast mass.
   
  The size of the tumor was greater than or equal to 5
   
  cm
   in 62 patients; it was localized in the supero external quadrant 41 times or 47.1%. Molecular classification revealed the following results: Luminal A 21.4%; receptive (HER2) positive 28.6%, and triple negative 42.9%.
   
  Stage II was the most represented with 47.4%. Histology found infiltrating carcinoma of non-specific type in 76 patients.
   
  The treatment was mastectomy axillary dissection in 66 patients, quadrantectomy + axillary dissection in 6 cases (6.9%) associated with radiotherapy in 6 patients, chemotherapy was performed in 79 of our patients and hormone therapy in 10 patients.
   
  <b>Conclusion:</b>
   Breast cancer is frequent in our country. Patients generally consult us at a late stage. The possibility of determining certain receptors and carrying out certain non-surgical treatments on site would improve the prognosis.
 
</p></abstract><kwd-group><kwd>Breast Cancer</kwd><kwd> Young Woman</kwd><kwd> Receptors</kwd><kwd> Diagnosis</kwd><kwd> Prognosis</kwd><kwd> Mali</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Breast cancer is a malignant neoformation that develops at the expense of the various constituents of the mammary gland [<xref ref-type="bibr" rid="scirp.121396-ref1">1</xref>]. Breast cancer accounts for 11.6% of cancer incidence. An estimated 2.1 million women are diagnosed with breast cancer. It is the most common in 154 of the 185 countries covered by GLOBOCAN 2018 and is the 5th leading cause of cancer death in women with 15% of deaths due to the disease [<xref ref-type="bibr" rid="scirp.121396-ref2">2</xref>].</p><p>For a long time, breast cancer was linked to a more or less advanced age. However, in recent literature, breast cancer is increasingly diagnosed in young people, its frequency is estimated at 7% of all cases of breast cancer. Thus, several studies have highlighted a number of factors involved in the etiology of this cancer. Among the main factors studied to date are endogenous and exogenous hormonal factors, factors related to reproduction, genetic and health factors, and finally factors related to lifestyle and nutrition [<xref ref-type="bibr" rid="scirp.121396-ref3">3</xref>].</p><p>The age threshold that should be considered as “young age” associated with a higher frequency of the above characteristics is not very clear in the literature, varying from 35 to 40 or even 45 years. In this manuscript, we have chosen the age of 40 as the threshold [<xref ref-type="bibr" rid="scirp.121396-ref4">4</xref>].</p><p>In France, breast cancer is the most common cancer in women with a constantly increasing incidence for 20 years, the number of new cases estimated in 2015 is 54,062 and occurs in 22% of women under 40 years old. In 7 years, 2083 patients with invasive breast cancer have been treated in the Gynecology department of the University Hospital of Tours in France. Among these women, 7.4% were less than or equal to 40 years old (7.4%) [<xref ref-type="bibr" rid="scirp.121396-ref5">5</xref>].</p><p>Miss JABA Sihan had a 40% incidence of breast cancer in women under 40 in Rabat, Morocco [<xref ref-type="bibr" rid="scirp.121396-ref6">6</xref>].</p><p>In Mali in 2017 Zeinabou Coulibaly found 19.68% of breast cancer in women under 40 [<xref ref-type="bibr" rid="scirp.121396-ref7">7</xref>].</p><p>As with other breast cancers, the diagnosis of breast cancer in young women is based on a careful clinical examination, mammography, breast ultrasound, and especially a histological examination of the tumor.</p><p>The management is consensual and is designed in a multidisciplinary consultation meeting which makes it possible to validate the therapeutic options.</p><p>Only early detection improves the prognosis of this cancer. This requires self-examination but also regular episodes of mammography [<xref ref-type="bibr" rid="scirp.121396-ref8">8</xref>].</p><p>Detection of metastatic disease at the subclinical stage does not improve survival. But early detection of local recurrences has a beneficial impact on survival [<xref ref-type="bibr" rid="scirp.121396-ref9">9</xref>].</p><p>In Mali, few studies have been carried out on breast cancer in young women, which motivated us to initiate this work.</p></sec><sec id="s2"><title>2. Objective</title><p>To determine the frequency of breast cancer in young women; to describe the risk factors for breast cancer in young women; to develop the diagnostic approach of the disease; to identify the different therapeutic strategies.</p></sec><sec id="s3"><title>3. Methodology</title><p>This was a retrospective and descriptive study going from January 2005 to December 2021, a period of 17 years, and included all cases of breast cancer in women aged 40 and under, operated and with a histological diagnosis. Data confidentiality was respected. The names of the patients do not appear in any document relating to the results of this study.</p></sec><sec id="s4"><title>4. Results</title><p>During our study we found 265 patients operated on for breast cancer, 87 of whom were aged 40 and under, at 32.83% of cases.</p><p>The age group [36 - 40 years] was the most frequent at 46%. The average age was 33.21 years with a standard deviation of 6.9 and extremes of 15 and 40 years (<xref ref-type="table" rid="table1">Table 1</xref>).</p><p>The family history of breast cancer was found in 09 cases at 10.3% (<xref ref-type="table" rid="table2">Table 2</xref>).</p><p>The menarche was late (greater than or equal to 16 years) in 9 of our patients (<xref ref-type="table" rid="table3">Table 3</xref>)</p><p>The majority of our patients had 4 as parity in 20.7% of cases followed by 03 and 5 which represented respectively 17.2% and 16.1% of cases (<xref ref-type="table" rid="table4">Table 4</xref>).</p><p>75.9% of our patients had consulted for a breast mass (<xref ref-type="table" rid="table5">Table 5</xref>).</p><p>There was breast pain in 57.5% of cases (<xref ref-type="table" rid="table6">Table 6</xref>).</p><p>There was skin ulceration in 33.3% of cases (<xref ref-type="table" rid="table7">Table 7</xref>).</p><p>The masses were localized in 47.1% of cases in the supero-external quadrant followed by the supero-internal quadrant in 11.5% of cases (<xref ref-type="table" rid="table8">Table 8</xref>).</p><p>The mean height was 07.6 cm with extremes of 1 and 27 cm and a standard deviation of 6.01 (<xref ref-type="table" rid="table9">Table 9</xref>).</p><p>ACR3 was the most represented, 26.4% of cases (<xref ref-type="table" rid="table1">Table 1</xref>0).</p><p>Breast ultrasound was not performed in 34.5% of patients. Ella was contributory in 65.5% (<xref ref-type="table" rid="table1">Table 1</xref>1).</p><p>Infiltrating carcinoma of the non-specific type was the most represented in 87.3% of cases, followed by breast carcinoma which is at 5.7% (<xref ref-type="table" rid="table1">Table 1</xref>2).</p><p>SBR-EE grade 2 was the most represented in 50.6% of cases (<xref ref-type="table" rid="table1">Table 1</xref>3).</p><p>The triple negative was the most represented at 42.9% (<xref ref-type="table" rid="table1">Table 1</xref>4).</p><p>60% des m&#233;tastases &#233;taient osseuse suivit du foie et des poumons qui repr&#233;sentait chacun 20% des cas (<xref ref-type="table" rid="table1">Table 1</xref>5).</p><p>Stage 2 was the most represented with 47.2% of cases followed by stage 3 which represented 37.9% of cases (<xref ref-type="table" rid="table1">Table 1</xref>6).</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Distribution of patients according to age (in years)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Age</th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Less than or equal to 15</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.1</td></tr><tr><td align="center" valign="middle" >16 &#224; 20</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >5.7</td></tr><tr><td align="center" valign="middle" >21 &#224; 25</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >9.2</td></tr><tr><td align="center" valign="middle" >26 &#224; 30</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >12.6</td></tr><tr><td align="center" valign="middle" >31 &#224; 35</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >25.3</td></tr><tr><td align="center" valign="middle" >36 &#224; 40</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >46</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Distribution of patients according to family history of breast cancer</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >History of breast cancer</th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >breast cancer</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >11.5</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >77</td><td align="center" valign="middle" >88.5</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Distribution of patients according to age of onset of menarche</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >menarche</th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >11</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.2</td></tr><tr><td align="center" valign="middle" >12</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >9.2</td></tr><tr><td align="center" valign="middle" >13</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >24.1</td></tr><tr><td align="center" valign="middle" >14</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >37.9</td></tr><tr><td align="center" valign="middle" >15</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >17.2</td></tr><tr><td align="center" valign="middle" >16</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >6.9</td></tr><tr><td align="center" valign="middle" >17</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2.3</td></tr><tr><td align="center" valign="middle" >18</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.2</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Distribution of patients according to parity</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >parity</th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >0</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >8</td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >12.6</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >10.3</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >17.2</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >20.7</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >16.1</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >6.9</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >4.6</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2.4</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.2</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Distribution of patients according to the reason for consultation</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Reason for consultation</th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >breast mass</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" >75.9</td></tr><tr><td align="center" valign="middle" >breast pain</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >12.6</td></tr><tr><td align="center" valign="middle" >Nipple discharge</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >4.6</td></tr><tr><td align="center" valign="middle" >Breast wound</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >4.6</td></tr><tr><td align="center" valign="middle" >Breast pruritus</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.2</td></tr><tr><td align="center" valign="middle" >Breast ulceration</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.2</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Distribution of patients according to the existence of breast pain</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Breast pain</th><th align="center" valign="middle" >Frequency</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >42.5</td></tr><tr><td align="center" valign="middle" >yes</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >57.5</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table7" ><label><xref ref-type="table" rid="table7">Table 7</xref></label><caption><title> Distribution of patients according to the existence of skin ulceration</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Skin ulceration</th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >58</td><td align="center" valign="middle" >66.7</td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >33.3</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table8" ><label><xref ref-type="table" rid="table8">Table 8</xref></label><caption><title> Distribution of patients according to tumor location</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Tumor location</th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Supero-outer quadrant Supero-inner quadrant Infero-outer quadrant</td><td align="center" valign="middle" >41 10 4</td><td align="center" valign="middle" >47.1 11.5 4.6</td></tr><tr><td align="center" valign="middle" >Inner lower quadrant</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >5.8</td></tr><tr><td align="center" valign="middle" >Outer and inner supero quadrant</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >8</td></tr><tr><td align="center" valign="middle" >Outer and inner lower quadrant</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >4.6</td></tr><tr><td align="center" valign="middle" >Retro areolar</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >8</td></tr><tr><td align="center" valign="middle" >whole breast</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >10.3</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table9" ><label><xref ref-type="table" rid="table9">Table 9</xref></label><caption><title> Distribution of patients according to tumor size</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Tumor size (cm)</th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Less than or equal to 2 2 &#224; 5</td><td align="center" valign="middle" >2 23</td><td align="center" valign="middle" >2.3 26.4</td></tr><tr><td align="center" valign="middle" >greater than or equal to 5</td><td align="center" valign="middle" >62</td><td align="center" valign="middle" >71.3</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table10" ><label><xref ref-type="table" rid="table1">Table 1</xref>0</label><caption><title> Distribution of patients according to the result of the mammography</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Mammography</th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >ACR1</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.2</td></tr><tr><td align="center" valign="middle" >ACR2</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >24.1</td></tr><tr><td align="center" valign="middle" >ACR3</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >26.4</td></tr><tr><td align="center" valign="middle" >ACR4</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >19.5</td></tr><tr><td align="center" valign="middle" >ACR5</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >3.5</td></tr><tr><td align="center" valign="middle" >ACR6</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.2</td></tr><tr><td align="center" valign="middle" >NOT DONE</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >24.1</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table11" ><label><xref ref-type="table" rid="table1">Table 1</xref>1</label><caption><title> Distribution of patients according to the result of the breast ultrasound</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Breast ultrasound</th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Hyper echogenic</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >5.7</td></tr><tr><td align="center" valign="middle" >Hypo echogenic</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >39.1</td></tr><tr><td align="center" valign="middle" >Fluid infiltration</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2.3</td></tr><tr><td align="center" valign="middle" >Heterogeneous mass</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >5.7</td></tr><tr><td align="center" valign="middle" >Suspicious mass</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >6.9</td></tr><tr><td align="center" valign="middle" >tissue mass</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.2</td></tr><tr><td align="center" valign="middle" >Inflammatory mastitis</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.2</td></tr><tr><td align="center" valign="middle" >Normal</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >3.4</td></tr><tr><td align="center" valign="middle" >Not made</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >34.5</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table12" ><label><xref ref-type="table" rid="table1">Table 1</xref>2</label><caption><title> Distribution of patients according to histology result</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Histological Type</th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Breast adenocarcinoma</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.2</td></tr><tr><td align="center" valign="middle" >Invasive carcinoma of non-specific type</td><td align="center" valign="middle" >76</td><td align="center" valign="middle" >87.3</td></tr><tr><td align="center" valign="middle" >Breast carcinoma</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >5.7</td></tr><tr><td align="center" valign="middle" >Medullary carcinoma</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.2</td></tr><tr><td align="center" valign="middle" >Invasive papillary carcinoma</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.2</td></tr><tr><td align="center" valign="middle" >Phyllodes tumor</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >3.4</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table13" ><label><xref ref-type="table" rid="table1">Table 1</xref>3</label><caption><title> Distribution of patients according to SBR-EE grade</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >SBR-EE grade</th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Grade 1</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >17.2</td></tr><tr><td align="center" valign="middle" >Grade 2</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" >50.6</td></tr><tr><td align="center" valign="middle" >Grade 3</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >32.2</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table14" ><label><xref ref-type="table" rid="table1">Table 1</xref>4</label><caption><title> Distribution of patients according to immunohistochemistry result</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Immunohistochemistry</th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Triple negative</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >42.9</td></tr><tr><td align="center" valign="middle" >luminal B</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >7.1</td></tr><tr><td align="center" valign="middle" >Luminal A</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >21.4</td></tr><tr><td align="center" valign="middle" >HER2+</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >28.6</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table15" ><label><xref ref-type="table" rid="table1">Table 1</xref>5</label><caption><title> Distribution of patients according to site of metastasis</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Site of metastasis</th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Hepatic</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >20</td></tr><tr><td align="center" valign="middle" >bone</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >60</td></tr><tr><td align="center" valign="middle" >Pulmonary</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >20</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table16" ><label><xref ref-type="table" rid="table1">Table 1</xref>6</label><caption><title> Distribution of patients according to TNM stage</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >TNM stage</th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Stade 1</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >3.4</td></tr><tr><td align="center" valign="middle" >Stade 2</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >47.2</td></tr><tr><td align="center" valign="middle" >Stade 3</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >37.9</td></tr><tr><td align="center" valign="middle" >Stade 4</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >11.5</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><p>Chemotherapy was performed in 90.2% of cases (<xref ref-type="table" rid="table1">Table 1</xref>7).</p><p>6.9% of patients had benefited from radiotherapy (<xref ref-type="table" rid="table1">Table 1</xref>8).</p><p>10 patients or 11.5% had benefited from hormone therapy against 88.5% (<xref ref-type="table" rid="table1">Table 1</xref>9).</p><p>The most performed type of surgery was mastectomy associated with axillary dissection, i.e. in 75.9% of cases (<xref ref-type="table" rid="table2">Table 2</xref>0).</p><p>The postoperative course was simple in 89.7% of cases. A recurrence was found in 4.6% of cases (<xref ref-type="table" rid="table2">Table 2</xref>1).</p></sec><sec id="s5"><title>5. Comments</title><p>We found a prevalence of 32.8% of breast cancer in young women (<xref ref-type="table" rid="table2">Table 2</xref>2), which is comparable to those of Samira in Marrakech [<xref ref-type="bibr" rid="scirp.121396-ref10">10</xref>] and Bouzid in Tunisia [<xref ref-type="bibr" rid="scirp.121396-ref11">11</xref>] who had respectively 18.6%, 10% and 7.5%; which is however different from the study by Znati et al. in Morocco [<xref ref-type="bibr" rid="scirp.121396-ref9">9</xref>].</p><p>11.5% of patients in our study had a personal history of breast pathology which was not proportional to those found by Bouzid et al. in Tunisia [<xref ref-type="bibr" rid="scirp.121396-ref11">11</xref>] and Jaba in Morocco [<xref ref-type="bibr" rid="scirp.121396-ref12">12</xref>]. Our study was statistically proportional to that of Samira in Marrakech [<xref ref-type="bibr" rid="scirp.121396-ref10">10</xref>] in 2019 (<xref ref-type="table" rid="table2">Table 2</xref>3).</p><table-wrap id="table17" ><label><xref ref-type="table" rid="table1">Table 1</xref>7</label><caption><title> Distribution of patients according to the feasibility of chemotherapy</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Chemotherapy</th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >9.2</td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >79</td><td align="center" valign="middle" >90.8</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table18" ><label><xref ref-type="table" rid="table1">Table 1</xref>8</label><caption><title> Distribution of patients according to the feasibility of radiotherapy</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Radiotherapy</th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >81</td><td align="center" valign="middle" >93.1</td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >6.9</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table19" ><label><xref ref-type="table" rid="table1">Table 1</xref>9</label><caption><title> Distribution of patients according to the feasibility of hormone therapy</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Hormone Therapy</th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >77</td><td align="center" valign="middle" >88.5</td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >11.5</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table20" ><label><xref ref-type="table" rid="table2">Table 2</xref>0</label><caption><title> Distribution of patients according to the type of surgery performed</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Type of surgery</th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Tumor excision</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.1</td></tr><tr><td align="center" valign="middle" >cleanliness mastectomy</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >16.1</td></tr><tr><td align="center" valign="middle" >Mastectomy plus axillary dissection</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" >75.9</td></tr><tr><td align="center" valign="middle" >Quadrantectomy</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >6.9</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table21" ><label><xref ref-type="table" rid="table2">Table 2</xref>1</label><caption><title> Distribution of patients according to postoperative course</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Complication Surgery</th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >None</td><td align="center" valign="middle" >78</td><td align="center" valign="middle" >89.6</td></tr><tr><td align="center" valign="middle" >Disunity</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.2</td></tr><tr><td align="center" valign="middle" >Infection</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.2</td></tr><tr><td align="center" valign="middle" >Lymphedema</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >3.4</td></tr><tr><td align="center" valign="middle" >Recidivism</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >4.6</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><p>In our series, we had 9 cases of family history of breast cancer at 10.3% proportional to 19.4% in the Senegalese series of Gueye et al. [<xref ref-type="bibr" rid="scirp.121396-ref13">13</xref>], to 15.3% in the Tunisian series of Bouzid [<xref ref-type="bibr" rid="scirp.121396-ref11">11</xref>] and 11.4% of the French series by M Guendouz et al. [<xref ref-type="bibr" rid="scirp.121396-ref14">14</xref>]. We do not have technology for the detection of genetic factors of breast cancer in Mali (<xref ref-type="table" rid="table2">Table 2</xref>4).</p><table-wrap id="table22" ><label><xref ref-type="table" rid="table2">Table 2</xref>2</label><caption><title> Frequency/authors</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Authors</th><th align="center" valign="middle" >Percentage</th><th align="center" valign="middle" >Statistical test</th></tr></thead><tr><td align="center" valign="middle" >Samira Marrakech 2019 n = 78 [<xref ref-type="bibr" rid="scirp.121396-ref10">10</xref>]</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >0.0000579</td></tr><tr><td align="center" valign="middle" >Bouzid Tunisie 2013 n = 124 [<xref ref-type="bibr" rid="scirp.121396-ref11">11</xref>] <sub> </sub></td><td align="center" valign="middle" >7.5</td><td align="center" valign="middle" >0.00000268</td></tr><tr><td align="center" valign="middle" >Znati Maroc 2010 n = 74 [<xref ref-type="bibr" rid="scirp.121396-ref9">9</xref>]</td><td align="center" valign="middle" >18.6</td><td align="center" valign="middle" >0.1776</td></tr><tr><td align="center" valign="middle" >Our study Mali 2021 n = 87</td><td align="center" valign="middle" >32.8</td><td align="center" valign="middle" >----</td></tr></tbody></table></table-wrap><table-wrap id="table23" ><label><xref ref-type="table" rid="table2">Table 2</xref>3</label><caption><title> Personal history of breast disease</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Authors</th><th align="center" valign="middle" >Breast pathology (%)</th><th align="center" valign="middle" >Statistical test</th></tr></thead><tr><td align="center" valign="middle" >Bouzid Tunisie 2013 [<xref ref-type="bibr" rid="scirp.121396-ref11">11</xref>] n = 124</td><td align="center" valign="middle" >3.22</td><td align="center" valign="middle" >0.0292</td></tr><tr><td align="center" valign="middle" >Jaba Maroc 2016 [<xref ref-type="bibr" rid="scirp.121396-ref12">12</xref>] n = 23</td><td align="center" valign="middle" >4.34</td><td align="center" valign="middle" >0.0522</td></tr><tr><td align="center" valign="middle" >Samira Marrakech [<xref ref-type="bibr" rid="scirp.121396-ref10">10</xref>] 2019 n = 78</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >0.414</td></tr><tr><td align="center" valign="middle" >Our study Mali 2021 n = 87<sub> </sub></td><td align="center" valign="middle" >11.5</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><table-wrap id="table24" ><label><xref ref-type="table" rid="table2">Table 2</xref>4</label><caption><title> Family history of breast cancer</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Authors</th><th align="center" valign="middle" >Background</th><th align="center" valign="middle" >Statistical test</th></tr></thead><tr><td align="center" valign="middle" >Gueye 2016 S&#233;n&#233;gal n = 62 [<xref ref-type="bibr" rid="scirp.121396-ref13">13</xref>]</td><td align="center" valign="middle" >12 (19.4%)</td><td align="center" valign="middle" >0.0824</td></tr><tr><td align="center" valign="middle" >Guendouz 2004 France n = 612 [<xref ref-type="bibr" rid="scirp.121396-ref14">14</xref>]</td><td align="center" valign="middle" >70 (11.4)</td><td align="center" valign="middle" >0.589</td></tr><tr><td align="center" valign="middle" >Bouzid Tunisie 2013 n = 124 [<xref ref-type="bibr" rid="scirp.121396-ref11">11</xref>]</td><td align="center" valign="middle" >19 (15.3)</td><td align="center" valign="middle" >0.264</td></tr><tr><td align="center" valign="middle" >Our study Mali2021 n = 87</td><td align="center" valign="middle" >9 (10.3%)</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>The study by Khanfir et al. in Tunisia found a predominance of stage III with 16.3% (<xref ref-type="table" rid="table2">Table 2</xref>5), which is proportional to our study and that of M Guendouz et al. in France with 37.9% and 38% respectively.</p><p>Thus, grade II of the SBR classification represented 50.6% of cases in our series (<xref ref-type="table" rid="table2">Table 2</xref>6 &amp; <xref ref-type="table" rid="table2">Table 2</xref>7). This is consistent with data from Bouzid in Tunisia. Grade 3 was the most represented in the study by Fleurier et al. [<xref ref-type="bibr" rid="scirp.121396-ref17">17</xref>] in France and that of Ayyad [<xref ref-type="bibr" rid="scirp.121396-ref16">16</xref>] in Morocco, i.e. in 49% of cases for each.</p><p>In our series, we found a predominance of mastectomy associated with axillary dissection (MCA). They were found in 66 patients 75.9% (<xref ref-type="table" rid="table2">Table 2</xref>8). This is related to the study by Jaba in Morocco [<xref ref-type="bibr" rid="scirp.121396-ref12">12</xref>] on 23 cases of breast cancer in young women, shows that 82% of patients had benefited from a mastectomy plus axillary dissection. The study by Bouzid et al. [<xref ref-type="bibr" rid="scirp.121396-ref11">11</xref>] had a rate of mastectomy plus axillary dissection in 63.5% of cases, which is proportional to ours.</p><p>Our study found 90.8% of cases of use of chemotherapy as treatment (<xref ref-type="table" rid="table2">Table 2</xref>9). This result is in line with the results of other authors such as Guendouz in France [<xref ref-type="bibr" rid="scirp.121396-ref14">14</xref>] with p = 0.1253, Bouzid in Tunisia with a p = 0.4071 and Gueye who found 89% of chemotherapy benefited in his study, with p = 0.2492. This could be explained by the sample size.</p><p>In our study, 11.5% of patients benefited from hormonal treatment (<xref ref-type="table" rid="table3">Table 3</xref>0). This rate is relatively low compared to those of other authors such as Khanfir</p><table-wrap id="table25" ><label><xref ref-type="table" rid="table2">Table 2</xref>5</label><caption><title> TNM stage/authors</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Authors</th><th align="center" valign="middle" >Stage III</th><th align="center" valign="middle" >Stage IV</th></tr></thead><tr><td align="center" valign="middle" >Khanfir Tunisie [<xref ref-type="bibr" rid="scirp.121396-ref15">15</xref>] 2006 n = 72</td><td align="center" valign="middle" >16.3 p = 0.00036</td><td align="center" valign="middle" >7 p = 0.229</td></tr><tr><td align="center" valign="middle" >Guendouz France [<xref ref-type="bibr" rid="scirp.121396-ref14">14</xref>] 2010 n = 612</td><td align="center" valign="middle" >38 p = 0.557</td><td align="center" valign="middle" >21.5 p = 0.0407</td></tr><tr><td align="center" valign="middle" >Our study Mali 2021 n = 87</td><td align="center" valign="middle" >37.9</td><td align="center" valign="middle" >11.5</td></tr></tbody></table></table-wrap><table-wrap id="table26" ><label><xref ref-type="table" rid="table2">Table 2</xref>6</label><caption><title> Histology/authors</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Authors</th><th align="center" valign="middle" >Histology</th><th align="center" valign="middle" >Statistical test</th></tr></thead><tr><td align="center" valign="middle" >Guendouz France [<xref ref-type="bibr" rid="scirp.121396-ref14">14</xref>] 2010 n = 612</td><td align="center" valign="middle" >CCI 83%</td><td align="center" valign="middle" >0.276</td></tr><tr><td align="center" valign="middle" >Gueye Senegal [<xref ref-type="bibr" rid="scirp.121396-ref13">13</xref>] 2016 n = 62</td><td align="center" valign="middle" >CCI 85.5%</td><td align="center" valign="middle" >0.0487</td></tr><tr><td align="center" valign="middle" >Znati Maroc [<xref ref-type="bibr" rid="scirp.121396-ref9">9</xref>] 2010 n = 74</td><td align="center" valign="middle" >CCI 75.67%</td><td align="center" valign="middle" >0.0338</td></tr><tr><td align="center" valign="middle" >Our study Mali 2021 n = 87</td><td align="center" valign="middle" >CCI 87.4%</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><table-wrap id="table27" ><label><xref ref-type="table" rid="table2">Table 2</xref>7</label><caption><title> Grade SBR-EE/authors</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Authors</th><th align="center" valign="middle" >Grade SBR-EE</th><th align="center" valign="middle" >Statistical test</th></tr></thead><tr><td align="center" valign="middle" >Ayyad Maroc [<xref ref-type="bibr" rid="scirp.121396-ref16">16</xref>] 2010 n = 48</td><td align="center" valign="middle" >Grade 3 (49%)</td><td align="center" valign="middle" >0.4437</td></tr><tr><td align="center" valign="middle" >Bouzid Tunisie [<xref ref-type="bibr" rid="scirp.121396-ref11">11</xref>] 2013 n = 124</td><td align="center" valign="middle" >Grade 2 (41.1%)</td><td align="center" valign="middle" >0.10076</td></tr><tr><td align="center" valign="middle" >Fleurier France [<xref ref-type="bibr" rid="scirp.121396-ref17">17</xref>] 2017 n = 155</td><td align="center" valign="middle" >Grade 3 (49%)</td><td align="center" valign="middle" >0.4437</td></tr><tr><td align="center" valign="middle" >Notre &#233;tude Mali 2021 n = 87</td><td align="center" valign="middle" >Grade 2 (50.6%)</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><table-wrap id="table28" ><label><xref ref-type="table" rid="table2">Table 2</xref>8</label><caption><title> Authors/type surgery</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Authors</th><th align="center" valign="middle" >type of surgery</th><th align="center" valign="middle" >Statistical test</th></tr></thead><tr><td align="center" valign="middle" >Ayyad Maroc [<xref ref-type="bibr" rid="scirp.121396-ref18">18</xref>] 2010 n = 48</td><td align="center" valign="middle" >MCA 72.2%</td><td align="center" valign="middle" >0.3144</td></tr><tr><td align="center" valign="middle" >Jaba Maroc [<xref ref-type="bibr" rid="scirp.121396-ref12">12</xref>] 2016 n = 23</td><td align="center" valign="middle" >MCA 82%</td><td align="center" valign="middle" >0.1927</td></tr><tr><td align="center" valign="middle" >Bouzid Tunisie [<xref ref-type="bibr" rid="scirp.121396-ref11">11</xref>] 2013 n = 124</td><td align="center" valign="middle" >MCA 63.5%</td><td align="center" valign="middle" >0.0324</td></tr><tr><td align="center" valign="middle" >Notre &#233;tude Mali 2021 n = 87</td><td align="center" valign="middle" >MCA 75.9%</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><table-wrap id="table29" ><label><xref ref-type="table" rid="table2">Table 2</xref>9</label><caption><title> Authors/chemotherapy</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Authors</th><th align="center" valign="middle" >Chemotherapy</th><th align="center" valign="middle" >Statistical test</th></tr></thead><tr><td align="center" valign="middle" >Guendouz France [<xref ref-type="bibr" rid="scirp.121396-ref14">14</xref>] 2010 n = 612</td><td align="center" valign="middle" >95.9%</td><td align="center" valign="middle" >0.1253</td></tr><tr><td align="center" valign="middle" >Gueye Senegal [<xref ref-type="bibr" rid="scirp.121396-ref13">13</xref>] 2016 n = 62</td><td align="center" valign="middle" >87.1%</td><td align="center" valign="middle" >0.2492</td></tr><tr><td align="center" valign="middle" >Bouzid Tunisie [<xref ref-type="bibr" rid="scirp.121396-ref11">11</xref>] 2013 n = 124</td><td align="center" valign="middle" >89%</td><td align="center" valign="middle" >0.4071</td></tr><tr><td align="center" valign="middle" >Notre &#233;tude Mali 2021 n = 87</td><td align="center" valign="middle" >90.8%</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><table-wrap id="table30" ><label><xref ref-type="table" rid="table3">Table 3</xref>0</label><caption><title> Hormone therapy/authors</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Authors</th><th align="center" valign="middle" >Hormone Therapy</th><th align="center" valign="middle" >Statistical test</th></tr></thead><tr><td align="center" valign="middle" >Khanfir Tunisie [<xref ref-type="bibr" rid="scirp.121396-ref15">15</xref>] 2006 n = 72</td><td align="center" valign="middle" >50%</td><td align="center" valign="middle" >0.0000</td></tr><tr><td align="center" valign="middle" >Guendouz France [<xref ref-type="bibr" rid="scirp.121396-ref14">14</xref>] 2010 n = 612</td><td align="center" valign="middle" >36.1%</td><td align="center" valign="middle" >0.000023</td></tr><tr><td align="center" valign="middle" >Samira Maroc [<xref ref-type="bibr" rid="scirp.121396-ref10">10</xref>] 2019 n = 78</td><td align="center" valign="middle" >49%</td><td align="center" valign="middle" >0.00000</td></tr><tr><td align="center" valign="middle" >Notre &#233;tude Mali 2021 n = 87</td><td align="center" valign="middle" >11.5 %</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>Tunisie [<xref ref-type="bibr" rid="scirp.121396-ref15">15</xref>], Guendouz France [<xref ref-type="bibr" rid="scirp.121396-ref14">14</xref>] and Samira Maroc [<xref ref-type="bibr" rid="scirp.121396-ref10">10</xref>] who had 50%, 36.1% and 49% respectively. This is due to the difficulty of access of our patients to hormone therapy.</p></sec><sec id="s6"><title>6. Conclusion</title><p>Breast cancer is a real public health problem, the number of new cases continues to increase in our country. We collected 87 cases of breast cancer in women under 41 years old. Young age is often associated with anatomo-clinical and evolutionary parameters of poor prognosis, among which we can cite diagnostic delay, the frequency of advanced forms with a larger tumor size, more frequent histological lymph node involvement, a higher histological grade. Often high, more frequent locoregional and distant recurrences, and finally poor overall survival.</p></sec><sec id="s7"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s8"><title>Cite this paper</title><p>Amadou, M., Zakari, S., Yoro, S.B., Ibrahima, D., Amadou, B., Mahamadou, D., Boubacar, D.A., Bathio, T., Diassana, M., Tani, K., Adama, D.A., Amadou, T., Mamadou, D., Djibril, T., Moussa, K., H&#233;l&#232;ne, S.O., Lassana, K., Madiassa, K., Souleymane, D., Moussa, S., Mory, K., Tientigui, D.B., Alhassane, T. and Ad&#233;gn&#233;, T. (2022) Breast Cancer in Young Women about 87 Cases in the General Surgery Department CHU Gabriel Tour&#233;. Surgical Science, 13, 506-517. https://doi.org/10.4236/ss.2022.1311059</p></sec></body><back><ref-list><title>References</title><ref id="scirp.121396-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Kerbaum, S. (1998) Dictionnaire de m&amp;#233dicine Flammarion. 6eme edition, M&amp;#233decine Sciences Publications, Paris.</mixed-citation></ref><ref id="scirp.121396-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">OMS (2019, janvier 5) La forte augmentation du cancer du sein demande des r&amp;#233ponses. https://www.temoignages.re</mixed-citation></ref><ref id="scirp.121396-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Jaba, S. (2016) Cancer du Sein chez la femme jeune: Facteurs de risque et pr&amp;#233vention. Th&amp;#232se de M&amp;#233decine, &amp;#224 l’Universit&amp;#233 Mohamed V-RABAT, Rabat.</mixed-citation></ref><ref id="scirp.121396-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Foxcroft, L.M., Evans, E.B. and Porter, A.J. (2004) The Diagnosis of Breast Cancer in Women Younger than 40. Breast, 13, 297-306. https://doi.org/10.1016/j.breast.2004.02.012</mixed-citation></ref><ref id="scirp.121396-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Boisserie-Lacroix, M., Dos Santos, E., Lebiez-Michel, N., Galtier, J.B., Bouzgarrou, M. and Trillaud, H. (2004) Mammography in Younger Women: Interpretation of Abnormal Findings. Journal of Radiology, 85, 2135-2142. https://doi.org/10.1016/S0221-0363(04)97794-3</mixed-citation></ref><ref id="scirp.121396-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Vrieling, C., Collette, L., Fourquet, A., et al. (2003) Can Patient-, Treatment- and Pathology-Related Characteristics Explain the High Local Recurrence Rate Following Breast-Conserving Therapy in Young Patients? European Journal of Cancer, 39, 932-944. https://doi.org/10.1016/S0959-8049(03)00123-0</mixed-citation></ref><ref id="scirp.121396-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Rojas, M.P., Telaro, E., Russo, A., Moschetti, A., Coe, L., Fossati, R., et al. (2005) Follow Up Strategies for Women Treated for Early Breast Cancer. Cochrane Database of Systematic Reviews, 1, CD001768.</mixed-citation></ref><ref id="scirp.121396-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">(2009) Surveillance apr&amp;#232s traitement de cancer du sein. Recommandations de Saint Paul de Vence 2009. Oncologie, 11, 589-610. https://doi.org/10.1007/s10269-009-1821-y</mixed-citation></ref><ref id="scirp.121396-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Kalluri, R. and Zeisberg, M. (2006) Fibroblasts in Cancer. Nature Reviews Cancer, 6, 392-401. https://doi.org/10.1038/nrc1877</mixed-citation></ref><ref id="scirp.121396-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Kamina, P. (1984) Anatomie gyn&amp;#233cologique et obst&amp;#233tricale. Maloine, Paris, 459, 469, 471-476, 513.</mixed-citation></ref><ref id="scirp.121396-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Susane, L. (2008) Guiding 2008 Women though a Breast Cancer Diagnosis. A Supportive and Personal Approach. Fondation canadienne du cancer du seisn, Rabat, Maroc, 56.</mixed-citation></ref><ref id="scirp.121396-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Bouzid, N., Lahmar, R., Tebra, S. and Bouaouina, N. (2013) Cancer du sein chez la femme jeune de moins de 35 ans en Tunisie: &amp;#201tude r&amp;#233trospective a propos de 124 cas. Gyn&amp;#233cologie Obst&amp;#233trique &amp; Fertilit&amp;#233, 41, 356-360. https://doi.org/10.1016/j.gyobfe.2013.05.002</mixed-citation></ref><ref id="scirp.121396-ref13"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gueye</surname><given-names> et al. </given-names></name>,<etal>et al</etal>. (<year>2017</year>)<article-title>Cancer du sein chez la femme de moins de 35 ans: Aspects &amp;#233pid&amp;#233miologiques, cliniques, th&amp;#233rapeutiques et pronostiques &amp;#224 l'unit&amp;#233 de s&amp;#233nologie du CHU Aristide le Dante de Dakar par</article-title><source> The Pan African Medical Journal</source><volume> 27</volume>,<fpage> 251</fpage>-<lpage>257</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.121396-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Guendouz, H., et al. (2011) Cancer du sein de la femme de moins de 35 ans: &amp;#201tude r&amp;#233trospective &amp;#224 propos de 612 cas par. La Lettre du S&amp;#233nologue.</mixed-citation></ref><ref id="scirp.121396-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Kanambaye, D. (2003) Cancer gyn&amp;#233cologiques et mammaires. Etude &amp;#233pid&amp;#233miologique &amp;#224 l’H&amp;#244pital Gabriel Toure de 1999 &amp;#224 2001. Th&amp;#232se, M&amp;#233decine Bamako, Bamako, N&amp;#176 59.</mixed-citation></ref><ref id="scirp.121396-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">(2010) Cancer du Sein Chez La femme Jeune de Moins de 35 ANS (A propos de 48 cas). Th&amp;#232se Ayyad No: 111/10. http://www.chu-fes.ma/cancer-du-sein-chez-la-femme-jeune-de-moins-de-35-ans-a-propos-de-48-cas/</mixed-citation></ref><ref id="scirp.121396-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Burstein, H.J., Prestrud, A.A., Seidenfeld, J., et al. (2010) American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women with Hormone Receptor &amp;#340 Positive Breast Cancer. Journal of Clinical Oncology, 28, 3784-3796.</mixed-citation></ref><ref id="scirp.121396-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Foxcroft, L.M., Evans, E.B., Hirst, C. and Hicks, B.J. (2001) Presentation and Diagnosis of Adolescent Breast Disease. Breast, 10, 399-404. https://doi.org/10.1054/brst.2001.0292</mixed-citation></ref></ref-list></back></article>